RG# ITMN

Related by string. * RG# [001] . RG# [002] . RG# [003] : RG# cytosine nucleoside analog . ATI FirePro RG# . RG# nucleoside analog . PLX# RG# . RG# synthetic human . RG# MRI . Suzuki RG# . RG# #mg . inhibitor RG# . RG# MRAP / : InterMune ITMN . InterMune NASDAQ ITMN . Intermune ITMN . Intermune Inc ITMN . Inc. NASDAQ ITMN . ITMN . Nasdaq ITMN . compound ITMN . NASDAQ ITMN * *

Related by context. Frequent words. (Click for all words.) 69 nab paclitaxel 65 Phase 1b trial 64 CRx 64 HCV protease inhibitor 64 double blinded placebo 63 rNAPc2 62 tolerated dose MTD 62 blind randomized placebo 62 SCH # 62 LY# [002] 62 PEG Interferon lambda 62 safety tolerability pharmacokinetics 62 active comparator 62 Pegasys R 62 thymalfasin 61 plus gemcitabine 61 CR# vcMMAE 61 Phase 1b clinical 61 peginterferon alfa 2a 61 Navelbine 61 placebo controlled clinical 61 Pivotal Phase 60 BMS # 60 blinded placebo controlled 60 Azedra 60 blind randomized controlled 60 Allovectin 7 R 60 ISIS # 60 Phase III randomized 60 dose escalation trial 60 Phase Ib 59 randomized Phase III 59 multicenter randomized 59 PS# [001] 59 CXA 59 investigational oral 59 abiraterone acetate 59 integrase inhibitor 59 tipranavir 59 Phase 1b 59 Phase Ia 59 immunomodulator 59 nitazoxanide 59 Nexavar ® 59 NOXAFIL 59 vicriviroc 59 prospective observational 59 HER2 positive metastatic breast 59 BAY #-# 59 HGS ETR1 59 placebo controlled randomized 59 relapsed refractory multiple myeloma 59 pramlintide 59 orally bioavailable 59 Phase 2a trial 59 aflibercept 59 Empatic 59 CA4P 59 Amrubicin 59 talabostat 59 Phase IIa trial 59 INGN 58 LY# [003] 58 peginterferon alfa 2b 58 blind randomized 58 Phase 2b study 58 transcriptase inhibitor NNRTI 58 LEVADEX 58 antisense drug 58 generation antisense 58 Asentar 58 axitinib 58 placebo controlled studies 58 TMC# [001] 58 Phase 2b clinical 58 Phase 2a clinical 58 valopicitabine 58 imetelstat 58 temsirolimus 58 decitabine 58 raltegravir 58 tanespimycin 58 VQD 58 phase IIb 58 CoFactor 58 zileuton 58 placebo controlled 58 tesmilifene 58 ADXS# 57 LIALDA 57 investigational compound 57 Staccato loxapine 57 randomized placebo controlled 57 NGX# 57 mg QD 57 sustained virologic response 57 PRECiSE 57 intravenously administered 57 plus prednisone 57 KNS # 57 confirmatory Phase III

Back to home page